Stock 301060 SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Labway Clinical Laboratory Co., Ltd

Equities

301060

CNE100004RG8

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
10.2 CNY -0.49% Intraday chart for Shanghai Labway Clinical Laboratory Co., Ltd +12.09% -23.25%
04-26 Shanghai Labway Clinical Laboratory Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-02 Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023. CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 13,910 7,854 5,323
Enterprise Value (EV) 1 13,203 7,433 5,323
P/E ratio 60.1 x 12.7 x -37.6 x
Yield 0.86% 1.53% -
Capitalization / Revenue 7.82 x 1.87 x 3.18 x
EV / Revenue 7.42 x 1.77 x 3.18 x
EV / EBITDA 39.4 x 6.6 x 70.9 x
EV / FCF 340 x -19.6 x -
FCF Yield 0.29% -5.11% -
Price to Book 8.89 x 3.81 x -
Nbr of stocks (in thousands) 400,517 400,517 400,517
Reference price 2 34.73 19.61 13.29
Announcement Date 22-03-28 23-04-26 24-04-26
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,053 1,153 1,238 1,778 4,199 1,674
EBITDA 1 111.9 121.1 170.8 335 1,127 75.1
EBIT 1 92.12 106.5 156.9 294.1 1,069 25.89
Operating Margin 8.75% 9.23% 12.67% 16.54% 25.46% 1.55%
Earnings before Tax (EBT) 1 105.7 126.3 162.3 318 904.4 -153.2
Net income 1 73.39 92.24 110.4 203.8 617.3 -141.6
Net margin 6.97% 8% 8.91% 11.46% 14.7% -8.46%
EPS 2 0.2082 0.2617 0.3132 0.5783 1.541 -0.3535
Free Cash Flow 1 49.02 -49.5 72.6 38.83 -379.9 -
FCF margin 4.66% -4.29% 5.86% 2.18% -9.05% -
FCF Conversion (EBITDA) 43.8% - 42.51% 11.59% - -
FCF Conversion (Net income) 66.8% - 65.77% 19.05% - -
Dividend per Share 2 0.1800 0.1000 - 0.3000 0.3000 -
Announcement Date 20-11-18 20-11-18 21-05-21 22-03-28 23-04-26 24-04-26
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 483 485 533 707 421 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 49 -49.5 72.6 38.8 -380 -
ROE (net income / shareholders' equity) 6.47% 7.9% 10.9% 18.1% 37.8% -
ROA (Net income/ Total Assets) 4.15% 4.68% 6.83% 10.3% 22.8% -
Assets 1 1,767 1,969 1,616 1,983 2,703 -
Book Value Per Share 2 3.270 3.350 3.470 3.910 5.150 -
Cash Flow per Share 2 0.5800 0.7300 1.170 0.8800 1.660 -
Capex 1 73.3 39.5 44.5 119 230 399
Capex / Sales 6.97% 3.43% 3.6% 6.69% 5.48% 23.82%
Announcement Date 20-11-18 20-11-18 21-05-21 22-03-28 23-04-26 24-04-26
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
SHANGHAI LABWAY CLINICAL LABORATORY CO., LTD Stock Shanghai Labway Clinical Laboratory Co., Ltd
-23.25% 564M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.86% 8.35B
RADNET, INC. Stock RadNet, Inc.
+39.49% 3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-38.71% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.47B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.96% 2.36B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-13.97% 1.78B
FLEURY S.A. Stock Fleury S.A.
-19.73% 1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.78% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+8.32% 1.12B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. 301060 Stock
  4. Financials Shanghai Labway Clinical Laboratory Co., Ltd